Adès, L., Le Bras, F., Sebert, M., Kelaidi, C., Lamy, T., Dreyfus, F., Eclache, V., Delaunay, J., Bouscary, D., Visanica, S., Turlure, P., Bresler, A. G., Cabrol, M.-P., Banos, A., Blanc, M., Vey, N., Delmer, A., Wattel, E., Chevret, S. and Fenaux, P. (2012) “Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies”, Haematologica. Pavia, Italy, 97(2), pp. 213-218. doi: 10.3324/haematol.2011.045914.